Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

LIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2) (LPP2)

13 listopada 2026 zaktualizowane przez: Institut Pasteur de Lille

Effect of the Dietary Supplement LIPI-PROTECT-2 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.

This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-2.The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.

Przegląd badań

Szczegółowy opis

Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.LIPI-PROTECT-2 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-2 in adults with untreated moderate hypercholesterolemia.A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-2 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.The primary objective is to assess the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.Secondary objectives are to evaluate the effect of LIPI-PROTECT-2 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

20

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Nord
      • Lille, Nord, Francja, 59019
    • Vaucluse
      • Avignon, Vaucluse, Francja, 84140

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 65 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Men and women aged 18-65 years For women :If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the studyIf post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)
  • LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
  • Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
  • BMI between 20 and 35 kg/m² (inclusive)
  • Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
  • Willing to comply with study requirements
  • Signed informed consent

Exclusion Criteria:

  • Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
  • Subjects with triglyceride levels > 4 g/L
  • Subjects requiring immediate lipid-lowering therapy
  • Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
  • Subjects receiving beta-blockers and/or diuretics
  • Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
  • Subjects receiving anticoagulant therapy
  • Subjects receiving antiretroviral therapy
  • Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
  • Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function)
  • Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
  • Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
  • Subjects with an allergy to any of the components of LIPI-PROTECT-2 Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
  • Subjects participating in another clinical study or currently within the exclusion period of another study
  • Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Food supplement group

Three tablets of LIPI-PROTECT-2 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers

All subjects will consume 4 capsules per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 2 capsules in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 capsules in the evening during dinner. If a dose is missed, 1 capsule can be taken at the next dose

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
Ramy czasowe: To baseline at 3 months

To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
Ramy czasowe: To baseline at 3 months

To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3).

To baseline at 3 months
To evaluate the effect of LIPI-PROTECT-2 on LDL cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on Non HDL cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on total cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on HDL cholesterol.
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on triglycerides.
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on non HDL cholesterol/LDL (atherogenic index).
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on ratio LDL/HDL.
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on ratio total cholesterol/HDL.
Ramy czasowe: At baseline, 1 month and 3 months

Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio).

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on fasting blood glucose levels.
Ramy czasowe: At baseline, 1 month and 3 months

Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on weight.
Ramy czasowe: At baseline, 1 month and 3 months

Changes in weight (unit : kilograms) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on Body Mass Index (BMI).
Ramy czasowe: At baseline, 1 month and 3 months

Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on waist circumference.
Ramy czasowe: At baseline, 1 month and 3 months

Changes in waist circumference (unit: cm) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on arterial blood pressure
Ramy czasowe: At baseline, 1 month and 3 months

Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the effect of LIPI-PROTECT-2 on heart rate
Ramy czasowe: At baseline, 1 month and 3 months

Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3.

At baseline, 1 month and 3 months
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism: ASAT/ALAT, GGT
Ramy czasowe: At baseline and 3 months

Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 .

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism : Creatinine, bilirubin
Ramy czasowe: At baseline and 3 months

Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Urea
Ramy czasowe: At baseline and 3 months

Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Creatinine Phophoskinase (CPK)
Ramy czasowe: At baseline and 3 months

Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3.

At baseline and 3 months
To evaluate the safety of LIPI-PROTECT-2 on Renal metabolism : Lactate Deshydrogenase (LDH)
Ramy czasowe: At baseline and 3 months

Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3.

At baseline and 3 months
To assess adherence to LIPI-PROTECT-2 consumption by pillbox weighing
Ramy czasowe: At baseline, 1 month and 3 months

Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0).

At baseline, 1 month and 3 months
To assess self-reported adherence to LIPI-PROTECT-2 consumption
Ramy czasowe: At baseline, 1 month, 2 months and 3 months

Adherence assessed through participant self-reporting of supplement consumption and missed doses.

At baseline, 1 month, 2 months and 3 months
To assess adherence to LIPI-PROTECT-2 consumption by counting returned tablets
Ramy czasowe: At 3 months

Adherence assessed by counting the remaining tablets returned by participants at the end of the study.

At 3 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Krzesło do nauki: Coralie BERTHIER, PhD, Institut Pasteur of Lille

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

4 listopada 2026

Zakończenie podstawowe (Szacowany)

30 marca 2027

Ukończenie studiów (Szacowany)

30 marca 2027

Daty rejestracji na studia

Pierwszy przesłany

13 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 listopada 2026

Pierwszy wysłany (Rzeczywisty)

19 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

13 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj